抑制检查点激酶1/2在肺纤维化及继发性肺动脉高压中的潜力
本研究探讨检查点激酶1/2(CHK1/2)在特发性肺纤维化(IPF)及IPF合并继发性肺动脉高压(IPF+PH)中的作用。在IPF患者及动物模型的肺组织、重构肺动脉和分离的成纤维细胞中观察到DNA损伤标志物和CHK1/2表达增加。阻断CHK1/2可诱导DNA损伤过载,逆转疾病细胞的抗凋亡和纤维增殖表型,并干扰TGF-β1介导的成纤维细胞活化;使用LY2606368药理学抑制CHK1/2可减轻两种动物模型中的纤维化和肺血管重构,改善呼吸力学和血流动力学参数。
要点
- CHK1/2在IPF及IPF+PH的肺纤维化和血管重构中表达增加。
- 抑制CHK1/2可逆转疾病细胞的抗凋亡和纤维增殖表型。
- LY2606368抑制CHK1/2可改善动物模型的纤维化和血流动力学。
核心结论
- CHK1/2是肺纤维化的关键调节因子,抑制CHK1/2可能是IPF和IPF+PH的潜在新型治疗选择。
研究设计与样本
- 研究评估CHK1/2在IPF和IPF+PH发展及进展中的作用,采用IPF患者和动物模型的肺组织、重构肺动脉及分离的成纤维细胞,并在两种模拟IPF和IPF+PH的动物模型中进行药理学抑制实验。
主要发现
- IPF患者和动物模型的肺组织、重构肺动脉及分离成纤维细胞中DNA损伤标志物和CHK1/2表达增加。
- 阻断CHK1/2表达或活性诱导DNA损伤过载,逆转疾病细胞的抗凋亡和纤维增殖表型。
- 抑制CHK1/2足以干扰TGF-β1介导的成纤维细胞活化。
- 使用LY2606368药理学抑制CHK1/2减轻两种动物模型中的纤维化和肺血管重构,改善呼吸力学和血流动力学参数。
临床怎么用
- CHK1/2抑制可能作为IPF和IPF+PH的潜在治疗策略,但需进一步临床研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a chronic lung disease characterised by exuberant tissue remodelling and associated with high unmet medical needs. Outcomes are even worse when IPF results in secondary pulmonary hypertension (PH). Importantly, exaggerated resistance to cell death, excessive proliferation and enhanced synthetic capacity are key endophenotypes of both fibroblasts and pulmonary artery smooth muscle cells, suggesting shared molecular pathways. Under persistent injury, sustained activation of the DNA damage response (DDR) is integral to the preservation of cells survival and their capacity to proliferate. Checkpoint kinases 1 and 2 (CHK1/2) are key components of the DDR. The objective of this study was to assess the role of CHK1/2 in the development and progression of IPF and IPF+PH. METHODS AND RESULTS: Increased expression of DNA damage markers and CHK1/2 were observed in lungs, remodelled pulmonary arteries and isolated fibroblasts from IPF patients and animal models. Blockade of CHK1/2 expression or activity-induced DNA damage overload and reverted the apoptosis-resistant and fibroproliferative phenotype of disease cells. Moreover, inhibition of CHK1/2 was sufficient to interfere with transforming growth factor beta 1-mediated fibroblast activation. Importantly, pharmacological inhibition of CHK1/2 using LY2606368 attenuated fibrosis and pulmonary vascular remodelling leading to improvement in respiratory mechanics and haemodynamic parameters in two animal models mimicking IPF and IPF+PH. CONCLUSION: This study identifies CHK1/2 as key regulators of lung fibrosis and provides a proof of principle for CHK1/2 inhibition as a potential novel therapeutic option for IPF and IPF+PH.
引用
- Wu WH, Bonnet S, Shimauchi T, et al. Potential for inhibition of checkpoint kinases 1/2 in pulmonary fibrosis and secondary pulmonary hypertension. Thorax. 2021. PMID: 34226205. doi:10.1136/thoraxjnl-2021-217377
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。